lynparza

Lynparza tablets approved for NHS use in platinum-sensitive, BRCA-mutated ovarian, fallopian tube or peritoneal cancer

pharmafile | January 16, 2020 | News story | Sales and Marketing |  AstraZeneca, MSD, NHS, NICE, UK, lynparza 

It has been announced that tablet form of Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has secured recommendation from NICE  for the treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer in adult patients with a BRCA1 or BRCA2 mutation.

Data supplied in support of the case for the drug’s recommendation demonstrated that Lynparza presented a progression-free survival benefit of 19.1 months, compared to 5.5 months for placebo.

The decision means that Lynparza tablets will now be made available to NHS patients in England and Wales who have previously undergone at least three courses of platinum-based chemotherapy.  

While the therapy meets NICE’s end-of-life criteria and was deemed cost-effective in this group, it does not in patients who have only received two courses. As a result, NICE believes it has the potential to be cost-effective and has asked for further confirmatory data on overall survival benefit.

Advertisement

In the meantime, it has recommended that the drug be made available via the Cancer Drugs Fund in this patient population, which is estimated to be around 1,100.

NICE previously recommended Lynparza in capsule formulation for patients with a BRCA mutation who have previously received at least three courses of platinum-based chemo.

Matt Fellows

Related Content

NIHR chief scientific adviser visits Huddersfield health innovation campus

Professor Lucy Chappell, Chief Scientific Adviser to the Department of Health and Social Care and …

Five Facts about NHS and primary care

1 Primary care is the front door to the NHS, but it extends well beyond …

Major funding opportunity opens for early cancer diagnostics

Up to £25.4m in funding is available for collaborative projects developing technologies to improve the …

The Gateway to Local Adoption Series

Latest content